Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/343688

Lähdeviite

Harris , S B , Parente , E B & Karalliedde , J 2022 , ' Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies ' , Diabetes therapy , vol. 13 , no. 5 , pp. 913-930 . https://doi.org/10.1007/s13300-022-01247-7

Julkaisun nimi: Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes : Hypothetical Case Studies
Tekijä: Harris, Stewart B.; Parente, Erika B.; Karalliedde, Janaka
Tekijän organisaatio: CAMM - Research Program for Clinical and Molecular Metabolism
University of Helsinki
Nefrologian yksikkö
Päiväys: 2022-05
Kieli: eng
Sivumäärä: 18
Kuuluu julkaisusarjaan: Diabetes therapy
ISSN: 1869-6953
DOI-tunniste: https://doi.org/10.1007/s13300-022-01247-7
URI: http://hdl.handle.net/10138/343688
Tiivistelmä: Type 2 diabetes (T2D) is a progressive disease, with many individuals eventually requiring basal insulin therapy to maintain glycaemic control. However, there exists considerable therapeutic inertia to the prompt initiation and optimal titration of basal insulin therapy due to barriers that include fear of injections, hypoglycaemia, weight gain, and burdensome regimens. Hypoglycaemia is thought to be a major barrier to optimal glycaemic control and is associated with significant morbidity and mortality. Newer second-generation basal insulin analogues provide comparable glycaemic control with lower risk of hypoglycaemia compared with first-generation basal insulin analogues. The present review article discusses clinical evidence for one such second-generation basal insulin analogue, insulin glargine 300 U/mL (Gla-300), in the context of hypothetical case studies that are representative of individuals who may attend routine clinical practice. These case studies discuss individualised treatment needs for people with T2D who are insulin-naive or pre-treated. Clinical characteristics such as older age, frequent nocturnal hypoglycaemia, and renal impairment, which are known risk factors for hypoglycaemia, are also considered.
Avainsanat: Basal insulin analogues
Glycaemic control
Hypoglycaemia
Insulin glargine 300 U
mL
Type 2 diabetes
GLYCEMIC CONTROL
BASAL INSULIN
SEVERE HYPOGLYCEMIA
ELDERLY-PATIENTS
GLUCOSE CONTROL
100 UNITS/ML
PEOPLE
TRIAL
OUTCOMES
PATHOPHYSIOLOGY
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by_nc
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Harris2022_Arti ... UseOfInsulinGlargine30.pdf 851.9KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot